A Phase 1 interventional study of Voriconazole and Atazanavir in Human Immunodeficiency Virus Type 1 (HIV-1) and HIV Infections, sponsored by Bristol-Myers Squibb. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-10-25.
Sponsored by Bristol-Myers Squibb · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing atazanavir in HIV Infections — none open to participants now, 1 under way, 1 of them phase 3. atazanavir · HIV Infections.
Among the 73 studies testing atazanavir in HIV Infections, this one is the 20th largest by enrollment of the 69 interventional ones that give a count, is one of 9 that started in 2009, is one of 16 in phase 1, and was the 55th registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →None of the 73 studies testing atazanavir in HIV Infections is open now. The open studies under HIV Infections, anywhere →
atazanavir: first FDA approval 2003 (REYATAZ), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 10 · Phase 3 20 · Phase 4 25
First in 2000; this study’s year is marked. 9 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 185 is above the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 55 across the 69 interventional studies. Of the 68 that completed or were terminated, 25 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 73 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
77 studies in HIV Infections by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 73 finished, 9 (12%) have results posted.
Among the 77 studies in HIV Infections by Bristol-Myers Squibb, this one is the 17th largest by enrollment of the 48 interventional ones that give a count, is the only one that started in 2009, is one of 16 in phase 1, and was the 74th registered.
Bristol-Myers Squibb’s HIV Infections studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 73 studies testing atazanavir in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 77 in HIV Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study assesses the effects of voriconazole, 200 mg, administered twice daily (BID), on the steady-state pharmacokinetics of atazanavir administered as atazanavir/ritonavir, 300/100 mg once daily (QD), in healthy participants with functional CYP2C19 alleles. The study also reviews the effects of atazanavir/ritonavir, 300/100 mg QD, on the pharmacokinetics of voriconazole, 200 mg, BID in healthy participants with functional CYP2C19 alleles.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
This study's enrollment of 185 is above the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Browse HIV Infections studies →Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Acquired Immunodeficiency Syndrome. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Voriconazole
Drug: Atazanavir · Drug: Ritonavir
Drug: Voriconazole · Drug: Atazanavir · Drug: Ritonavir
Drug: Voriconazole
Drug: Voriconazole · Drug: Atazanavir · Drug: Ritonavir
Treatment A: Participants with functional CYP2C19 alleles (EM) received oral tablets of voriconazole, 400 mg, twice daily (BID), on Day 1, then 200 mg BID on Days 2 and 3. Voriconazole dose was given at least 1 hour after a light meal. Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal, and 1 hour before voriconazole morning dose. Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30.
Treatment B in EM participants: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), on Days 11 through 20. Treatment B in participants who were poor metabolizers of CYP2C19 (PMs): PM participants received oral tablets of atazanavir/ritonavir, 300/100 mg QD, on Days 11 through 20. Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg QD, plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30.
Also known as: Reyataz, BMS-232632
Treatment B: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), on Days 11 through 20. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal. Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg QD, plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal, and 1 hour before voriconazole morning dose.Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30. Treatment B in PM participants: PM participants received atazanavir/ritonavir, 300/100 mg QD, on Days 11 through 20. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal.
Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Cmin) of Atazanavir, Administered as Atazanavir/Ritonavir With and Without Voriconazole, in Participants Who Are Extensive Metabolizers (EM)
EM participants are those with functional CYP2C19 alleles.
Time frame: Predose and at 1, 2, 3, 4, 5, 7, 9,13, and 24 hours postdose on Days 20 and 30 of a 30-day cycle
Time to Maximum Concentration (Tmax) of Atazanavir, Administered as Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants
EM=extensive metabolizers, or participants with functional CYP2C19 alleles.
Time frame: Predose and at 1, 2, 3, 4, 5, 7, 9,13, and 24 hours postdose on Days 20 and 30 of a 30-day cycle
Area Under the Plasma Concentration-time Curve in 1 Dosing Interval [AUC(TAU)] of Atazanavir Administered as Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants
EM=extensive metabolizers, or participants with functional CYP2C19 alleles.
Time frame: Predose and at 1, 2, 3, 4, 5, 7, 9,13, and 24 hours postdose on Days 20 and 30 of a 30-day cycle
Tmax of Voriconazole, Administered With and Without Atazanavir/Ritonavir, in EM Participants
Tmax=time to maximum concentration; EM=extensive metabolizers, or participants with functional CYP2C19 alleles.
Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdoseDays 3 and 30 of a 30-day cycle
Cmax and Cmin of Voriconazole, Administered With and Without Atazanavir/Ritonavir, in EM Participants
Cmax=maximum observed plasma concentration; Cmin=minimum observed plasma concentration; EM=extensive metabolizers, or participants with functional CYP2C19 alleles.
Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdoseDays 3 and 30 of a 30-day cycle
AUC(TAU)of Voriconazole, Administered With and Without Atazanavir/Ritonavir, in EM Participants
AUC(TAU)=area under the plasma concentration-time curve in 1 dosing interval; EM=extensive metabolizers, or participants with functional CYP2C19 alleles.
Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdoseDays 3 and 30 of a 30-day cycle
Cmax and Cmin of Ritonavir, Administered As Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants
Cmax=maximum observed plasma concentration; Cmin=minimum observed plasma concentration; EM=extensive metabolizers, or participants with functional CYP2C19 alleles.
Time frame: Predose and at 1, 2, 3, 4, 5, 7, 9,13, and 24 hours postdose on Days 20 and 30 of a 30-day cycle
Tmax of Ritonavir, Administered As Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants
Tmax=time to maximum concentration; EM=extensive metabolizers, or participants with functional CYP2C19 alleles.
Time frame: Predose and at 1, 2, 3, 4, 5, 7, 9,13, and 24 hours postdose on Days 20 and 30 of a 30-day cycle
AUC(TAU) of Ritonavir, Administered As Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants
AUC(TAU)=area under the plasma concentration-time curve in 1 dosing interval; EM=extensive metabolizers, or participants with functional CYP2C19 alleles.
Time frame: Predose and at 1, 2, 3, 4, 5, 7, 9,13, and 24 hours postdose on Days 20 and 30 of a 30-day cycle
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Any AE
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Time frame: Days 1 to 31 (discharge), continuously
Number of Participants With Marked Abnormalities in Serum Chemistry Test Results
LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Safety criteria: AST and ALT: If \>1.25\*ULN, or if preRX\>ULN, use \>1.25\*preRX. Total and direct bilirubin: If \>1.1\*ULN or if preRX\>ULN, use \>1.25\*preRX. Creatinine: If \>1.33\*preRX. Serum glucose, fasting: If preRX\<LLN, use \<.8\*preRX or \>ULN; if preRX\>ULN, use \>2\*preRX or \<LLN. Creatinine kinase: If \>1.5\*ULN or preRX\>ULN, use \>1.5\*or preRX. Lactose dehydrogenase: If \>1.25\*ULN or preRX\>ULN, use \>1.5\*preRX.
Time frame: Within 21 days of Day 1 and on Days 3, 10, 20, 26, and 31 (at discharge)
Number of Participants With Marked Abnormalities in Hematology Laboratory Test and Urinalysis Results
LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Safety criteria: Neutrophils + bands: If \<.85\*LLN or \>1.15\*ULN or ULN or if preRX\<LLN, use \<0.85\*preRX or \>ULN; if preRX\>ULN, use \>1.15\*preRX or \<LLN. Lymphocytes, relative: If \<0.85\*LLN or \>1.15\*ULN, or if preRX \<LLN, use \<0.85\*preRX or \>ULN; if preRX \>ULN, use \>1.15\*preRX or \<LLN. Blood, urine: If \>= 2+, or if preRX \>=1+, use \>=2\*preRX. White blood cells, urine: If \>=2+, or if preRX \>=2+, use \>=4+. Red blood cells, urine: If \>=2+ or if preRX \>=2+, use \>=4+. Not all categories were evaluated for each arm.
Time frame: Within 21 days of Day 1 and on Days 3, 10, 20, 26, and 31 (at discharge)
Number of Participants With Investigator-identified Abnormalities in Electrocardiogram Results Not Present Prior to Administration of Study Drug and Considered Not Relevant and Not AEs by Investigator
volt=voltage; LVH=left ventricular hypertrophy
Time frame: Within 21 days of Day 1 and on Days -1, 21, and 31 (at discharge)
Number of Participants With Abnormalities in Vital Signs
Time frame: Within 21 days of Day 1 and on Days -1, 1, 3, 11, 21, and 31 (at discharge)
| Milestone | Voriconazole, 200 BID (EM) | Atazanavir/Ritonavir, 300/100 QD (EM) | Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM) | Voriconazole, 50 mg BID (PM) | Atanazivir/Ritonavir, 300/100 QD + Voriconazole, 50 BID (PM) | Atazanavir/Ritonavir, 300/100 QD (PM) |
|---|---|---|---|---|---|---|
| Started | 24 | 0 | 0 | 8 | 0 | 0 |
| Completed | 24 | 0 | 0 | 8 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Voriconazole, 200 BID (EM) | Atazanavir/Ritonavir, 300/100 QD (EM) | Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM) | Voriconazole, 50 mg BID (PM) | Atanazivir/Ritonavir, 300/100 QD + Voriconazole, 50 BID (PM) | Atazanavir/Ritonavir, 300/100 QD (PM) |
|---|---|---|---|---|---|---|
| Started | 0 | 24 | 0 | 0 | 0 | 8 |
| Completed | 0 | 21 | 0 | 0 | 0 | 8 |
| Not completed | 0 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Voriconazole, 200 BID (EM) | Atazanavir/Ritonavir, 300/100 QD (EM) | Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM) | Voriconazole, 50 mg BID (PM) | Atanazivir/Ritonavir, 300/100 QD + Voriconazole, 50 BID (PM) | Atazanavir/Ritonavir, 300/100 QD (PM) |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 21 | 0 | 8 | 0 |
| Completed | 0 | 0 | 20 | 0 | 7 | 0 |
| Not completed | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 |
EM participants are those with functional CYP2C19 alleles.
| ng/mL | Atazanavir/Ritonavir, 300/100 QD (EM) | Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM) |
|---|---|---|
| Atazanavir Cmin | 674 ± 61 | 525 ± 50 |
| Atazanavir Cmax | 4715 ± 27 | 4076 ± 23 |
EM=extensive metabolizers, or participants with functional CYP2C19 alleles.
| Hours | Atazanavir/Ritonavir, 300/100 QD (EM) | Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM) |
|---|---|---|
| Time to Maximum Concentration (Tmax) of Atazanavir, Administered as Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants | 3.0 (2.0 to 4.0) | 2.07 (2.0 to 4.0) |
EM=extensive metabolizers, or participants with functional CYP2C19 alleles.
| ng*h/mL | Atazanavir/Ritonavir, 300/100 QD (EM) | Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM) |
|---|---|---|
| Area Under the Plasma Concentration-time Curve in 1 Dosing Interval [AUC(TAU)] of Atazanavir Administered as Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants | 44634 ± 35 | 38276 ± 28 |
Cmax=maximum observed plasma concentration; Cmin=minimum observed plasma concentration; EM=extensive metabolizers, or participants with functional CYP2C19 alleles.
| ng/mL | Atazanavir/Ritonavir, 300/100 QD (EM) | Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM) |
|---|---|---|
| Ritonavir Cmax | 1597 ± 40 | 1429 ± 38 |
| Ritonavir Cmin | 37.1 ± 61 | 28.3 ± 69 |
Tmax=time to maximum concentration; EM=extensive metabolizers, or participants with functional CYP2C19 alleles.
| Hours | Atazanavir/Ritonavir, 300/100 QD (EM) | Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM) |
|---|---|---|
| Tmax of Ritonavir, Administered As Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants | 4.0 (1.5 to 5.0) | 4.0 (2.0 to 4.0) |
Tmax=time to maximum concentration; EM=extensive metabolizers, or participants with functional CYP2C19 alleles.
| Hours | Voriconazole, 200 BID (EM) | Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM) |
|---|---|---|
| Tmax of Voriconazole, Administered With and Without Atazanavir/Ritonavir, in EM Participants | 1.50 (0.5 to 3.0) | 1.25 (1.0 to 3.0) |
Cmax=maximum observed plasma concentration; Cmin=minimum observed plasma concentration; EM=extensive metabolizers, or participants with functional CYP2C19 alleles.
| ng/mL | Voriconazole, 200 BID | Atazanavir/Ritonavir, 300/100mg QD + Voriconazole, 200 mg BID |
|---|---|---|
| Voriconazole Cmax | 3416 ± 49 | 3014 ± 47 |
| Voriconazole Cmin | 776 ± 92 | 439 ± 144 |
AUC(TAU)=area under the plasma concentration-time curve in 1 dosing interval; EM=extensive metabolizers, or participants with functional CYP2C19 alleles.
| ng.h/mL | Voriconazole, 200 BID (EM) | Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM) |
|---|---|---|
| AUC(TAU)of Voriconazole, Administered With and Without Atazanavir/Ritonavir, in EM Participants | 20284 ± 65 | 12944 ± 89 |
AUC(TAU)=area under the plasma concentration-time curve in 1 dosing interval; EM=extensive metabolizers, or participants with functional CYP2C19 alleles.
| ng.h/mL | Atazanavir/Ritonavir, 300/100 QD (EM) | Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM) |
|---|---|---|
| AUC(TAU) of Ritonavir, Administered As Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants | 9572 ± 37 | 8280 ± 32 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
| Participants | Voriconazole, 200 BID (EM) | Atazanavir/Ritonavir, 300/100 QD (EM) | Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM) | Voriconazole, 50 mg BID (PM) | Atanazivir/Ritonavir, 300/100 QD + Voriconazole, 50 BID (PM) | Atazanavir/Ritonavir, 300/100 QD (PM) |
|---|---|---|---|---|---|---|
| Deaths | 0 | 0 | 0 | 0 | 0 | 0 |
| SAEs | 0 | 0 | 0 | 0 | 0 | 0 |
| AEs leading to discontinuation | 0 | 2 | 1 | 0 | 0 | 0 |
| Any AE | 22 | 24 | 21 | 0 | 3 | 2 |
LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Safety criteria: AST and ALT: If \>1.25\*ULN, or if preRX\>ULN, use \>1.25\*preRX. Total and direct bilirubin: If \>1.1\*ULN or if preRX\>ULN, use \>1.25\*preRX. Creatinine: If \>1.33\*preRX. Serum glucose, fasting: If preRX\<LLN, use \<.8\*preRX or \>ULN; if preRX\>ULN, use \>2\*preRX or \<LLN. Creatinine kinase: If \>1.5\*ULN or preRX\>ULN, use \>1.5\*or preRX. Lactose dehydrogenase: If \>1.25\*ULN or preRX\>ULN, use \>1.5\*preRX.
| Participants | Voriconazole, 200 BID (EM) | Atazanavir/Ritonavir, 300/100 QD (EM) | Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM) | Voriconazole, 50 mg BID (PM) | Atazanavir/Ritonavir, 300/100 QD + Voriconazole, 50 BID (PM) | Atazanavir/Ritonavir, 300/100 QD (PM) |
|---|---|---|---|---|---|---|
| Aspartate aminotransferase (AST) (U/L): High | 0 | 0 | 1 | 0 | 0 | 0 |
| Alanine aminotransferase (ALT) (U/L): High | 0 | 1 | 1 | 0 | 1 | 1 |
| Total bilirubin (mg/dL): High | 4 | 22 | 21 | 0 | 8 | 7 |
| Direct bilirubin (mg/dL): High | 0 | 0 | 0 | 0 | 2 | 2 |
| Creatinine (mg/dL): High | 0 | 0 | 0 | 0 | 0 | 1 |
| Serum glucose, fasting (mg/dL): Low | 1 | 0 | 0 | 0 | 0 | 0 |
| Creatine kinase (U/L): High | 0 | 1 | 3 | 0 | 0 | 0 |
| Lactase dehydrogenase (U/L): High | 1 | 1 | 0 | 0 | 0 | 0 |
LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Safety criteria: Neutrophils + bands: If \<.85\*LLN or \>1.15\*ULN or ULN or if preRX\<LLN, use \<0.85\*preRX or \>ULN; if preRX\>ULN, use \>1.15\*preRX or \<LLN. Lymphocytes, relative: If \<0.85\*LLN or \>1.15\*ULN, or if preRX \<LLN, use \<0.85\*preRX or \>ULN; if preRX \>ULN, use \>1.15\*preRX or \<LLN. Blood, urine: If \>= 2+, or if preRX \>=1+, use \>=2\*preRX. White blood cells, urine: If \>=2+, or if preRX \>=2+, use \>=4+. Red blood cells, urine: If \>=2+ or if preRX \>=2+, use \>=4+. Not all categories were evaluated for each arm.
| Participants | Voriconazole, 200 BID (EM) | Atazanavir/Ritonavir, 300/100 QD (EM) | Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM) | Voriconazole, 50 mg BID (PM) | Atanazivir/Ritonavir, 300/100 QD + Voriconazole, 50 BID (PM) | Atazanavir/Ritonavir, 300/100 QD (PM) |
|---|---|---|---|---|---|---|
| Neutrophils + bands(absolute)(*10^3 cells/uL): Low | 1 | 0 | 1 | 0 | 0 | 0 |
| Lymphocytes, relative (*10*3 cells/uL): Low | 1 | 1 | 1 | NA | NA | NA |
| Lymphocytes, relative (*10*3 cells/uL): High | 5 | 1 | 1 | NA | NA | NA |
| Blood, urine: High | 1 | 1 | 2 | 0 | 0 | 0 |
| White blood cells (WBC), urine: High | 1 | 0 | NA | NA | NA | NA |
| Red blood cells (RBC), urine: High | 1 | 0 | NA | NA | NA | NA |
volt=voltage; LVH=left ventricular hypertrophy
| Participants | Voriconazole, 200 BID (EM) | Atazanavir/Ritonavir, 300/100 QD (EM) | Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM) | Voriconazole, 50 mg BID (PM) | Atanazivir/Ritonavir, 300/100 QD + Voriconazole, 50 BID (PM) | Atazanavir/Ritonavir, 300/100 QD (PM) |
|---|---|---|---|---|---|---|
| Sinus bradycardia | 0 | 0 | 0 | 0 | 2 | 0 |
| ST elevation and fusion complexes | 0 | 0 | 0 | 0 | 1 | 0 |
| T-wave abnormality + minimum volt criteria for LVH | 0 | 0 | 0 | 0 | 1 | 0 |
| Nonspecific T-wave abnormality | 0 | 0 | 0 | 0 | 1 | 0 |
| Participants | Voriconazole, 200 BID (EM) | Atazanavir/Ritonavir, 300/100 QD (EM) | Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM) | Voriconazole, 50 mg BID (PM) | Atanazivir/Ritonavir, 300/100 QD + Voriconazole, 50 BID (PM) | Atazanavir/Ritonavir, 300/100 QD (PM) |
|---|---|---|---|---|---|---|
| Diastolic blood pressure | 0 | 0 | 0 | 0 | 0 | 0 |
| Systolic blood pressure | 0 | 0 | 0 | 0 | 0 | 0 |
| Heart rate | 0 | 0 | 0 | 0 | 0 | 0 |
| Respiratory rate | 0 | 0 | 0 | 0 | 0 | 0 |
| Temperature | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Days 1 through 30, continuously, of a 30-day cycle.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Voriconazole, 200 BID (EM) | — | 0/24 (0%) | 22/24 (91.7%) |
| Atazanavir/Ritonavir, 300/100 QD (EM) | — | 0/24 (0%) | 24/24 (100%) |
| Atazanavir/Ritonavir, 300/100 QD (PM) | — | 0/8 (0%) | 2/8 (25%) |
| Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM) | — | 0/21 (0%) | 17/21 (81%) |
| Voriconazole, 50 mg BID (PM) | — | 0/8 (0%) | 0/8 (0%) |
| Atazanazvir/Ritonavir, 300/100 QD + Voriconazole, 50 BID (PM) | — | 0/8 (0%) | 3/8 (37.5%) |
| Event | Voriconazole, 200 BID (EM) | Atazanavir/Ritonavir, 300/100 QD (EM) | Atazanavir/Ritonavir, 300/100 QD (PM) | Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM) | Voriconazole, 50 mg BID (PM) | Atazanazvir/Ritonavir, 300/100 QD + Voriconazole, 50 BID (PM) |
|---|---|---|---|---|---|---|
| HyperbilirubinaemiaHepatobiliary disorders | 2/24 | 15/24 | 0/8 | 0/21 | 0/8 | 0/8 |
| HeadacheNervous system disorders | 12/24 | 3/24 | 0/8 | 2/21 | 0/8 | 0/8 |
| PhotophobiaEye disorders | 10/24 | 0/24 | 0/8 | 4/21 | 0/8 | 0/8 |
| Ocular icterusEye disorders | 0/24 | 8/24 | 0/8 | 0/21 | 0/8 | 0/8 |
| Vision blurredEye disorders | 8/24 | 1/24 | 0/8 | 5/21 | 0/8 | 0/8 |
| JaundiceHepatobiliary disorders | 0/24 | 8/24 | 0/8 | 0/21 | 0/8 | 0/8 |
| PhotopsiaEye disorders | 4/24 | 0/24 | 0/8 | 6/21 | 0/8 | 0/8 |
| Blood bilirubin increasedInvestigations | 1/24 | 6/24 | 1/8 | 1/21 | 0/8 | 0/8 |
| DizzinessNervous system disorders | 6/24 | 1/24 | 0/8 | 3/21 | 0/8 | 0/8 |
| Visual impairmentEye disorders | 5/24 | 1/24 | 0/8 | 3/21 | 0/8 | 0/8 |
| Age Continuous(years) | Extensive Metabolizers (EM) | Poor Metabolizers (PM) | Total |
|---|---|---|---|
| Mean | 31 ± 10 | 30 ± 7 | 31 ± 9 |
| Sex: Female, Male(Participants) | Extensive Metabolizers (EM) | Poor Metabolizers (PM) | Total |
|---|---|---|---|
| Female | 4 | 0 | 4 |
| Male | 20 | 8 | 28 |
| Race/Ethnicity, Customized(participants) | Extensive Metabolizers (EM) | Poor Metabolizers (PM) | Total |
|---|---|---|---|
| Asian | 2 | 8 | 10 |
| Black or African American | 1 | 0 | 1 |
| White | 20 | 0 | 20 |
| Not reported | 0 | 0 | 0 |
| Other | 1 | 0 | 1 |
| CYP2C19 Genotype of Participants(Participants) | Extensive Metabolizers (EM) | Poor Metabolizers (PM) | Total |
|---|---|---|---|
| 1/1 | 11 | 0 | 11 |
| 1/2 | 5 | 0 | 5 |
| 1/17 | 6 | 0 | 6 |
| 2/2 | 0 | 6 | 6 |
| 2/3 | 0 | 1 | 1 |
| 2/17 | 1 | 0 | 1 |
| 17/17 | 1 | 0 | 1 |
| 3/3 | 0 | 1 | 1 |
The record gives a start of Sep 2009, a primary completion of Jul 2010 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Voriconazole · Atazanavir · Ritonavir